结合IL-33与PD-1阻断,可以增强mILC2s介导的抗瘤免疫力
Jiawei Yue1, Hui Guo2, Peng Xu1
1Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Cancer immunology, immunotherapy : CII
|March 2, 2024
概括
2组先天性淋巴细胞 (ILC2s) 在肺瘤中处于静止状态,但可以通过IL-33.3激活. 将IL-33与抗PD-1疗法结合起来可以增强抗瘤免疫力和免疫疗法的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
- 细胞生物学 细胞生物学
背景情况:
- 第二组先天性淋巴细胞 (ILC2s) 是组织中的关键细胞因子生产者.
- 它们在癌症免疫和免疫治疗中的作用尚不清楚.
研究的目的:
- 调查ILC2s在肺腺癌 (LUAD) 免疫中的作用.
- 探索IL-33和抗PD-1疗法的协同效应.
主要方法:
- 流细胞计量量化ILC2s,T细胞和PD-1表达.
- 免疫组织化学和免疫光检测IL-33和ILC2透.
主要成果:
- 在LUAD中的瘤内ILC2s处于静止状态,但被IL-33.3激活.
- 结合IL-33和抗PD-1疗法可以增强抗瘤免疫力.
- 这种组合上调激活成熟ILC2s (mILC2s),增强抗PD-1疗法.
结论:
- 在癌症免疫治疗中,ILC2s对抗瘤反应有显著的贡献.
- 针对ILC2s和T细胞都是一个有前途的免疫治疗策略.
相关概念视频
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


